Top

Published in:

01-01-2005 | Diagnostic Neuroradiology

Value of ¹²³I-IMT SPECT for diagnosis of recurrent non-astrocytic intracranial tumours

Authors: Michail Plotkin, Holger Amthauer, Julia Eisenacher, Reinhard Wurm, Roger Michel, Peter Wust, Florian Stockhammer, Rainer Röttgen, Matthias Gutberlet, Juri Ruf, Roland Felix

Published in: Neuroradiology | Issue 1/2005

Abstract

The value of single-photon emission tomography (SPECT) using iodine-123-alpha-methyl-tyrosine (IMT) for the diagnosis of recurrent or residual gliomas is well established. In the current study we investigated whether IMT-SPECT could also be useful in the follow-up of brain metastases and other intracranial tumours of non-astrocytic origin. The study included 22 patients with suspected recurrent intracranial tumours of non-astrocytic origin (12 brain metastases, one supratentorial primitive neuroendocrine tumour (PNET), one rhabdoid tumour, two clivus chordomas, three ependymomas, two pituitary tumours, one anaplastic meningioma) who had previously been treated by surgery and/or radio/chemotherapy. SPECT results were correlated with clinical and MRI follow-up data. The study was true positive in 13 patients, true negative in five, false positive in one and false negative in three patients. Notably, all false negative findings were <13 mm. The resulting sensitivity of the IMT-SPECT was 81%. We concluded that the IMT-SPECT is a promising complementary imaging tool for the detection of recurrences of non-astrocytic intracranial tumours and their distinguishing from treatment-induced changes. The limitation of the IMT-SPECT is its low sensitivity for the detection of small lesions.

Bergström M, Collins VP, Ehrin E, Ericson K, Ericson L, Greitz T, Halldin C, von Holst H, Langstrrom B, Lilja A, et al (1983) Discrepancies in brain tumor extent as shown by computed tomography and positron emission tomography using [68 Ga]EDTA, [11C]glucose, and [11C]methionine. J Comput Assist Tomogr 7:1062–1066PubMed

Tovi M, Lilja A, Bergstrom M, Ericsson A, Bergstrom K, Hartman M (1990) Delineation of gliomas with magnetic resonance imaging using Gd-DTPA in comparison with computed tomography and positron emission tomography. Acta Radiol 31:417–429

Lilja A, Lundqvist H, Olsson Y, Spannare B, Gullberg P, Langstrom B (1989) Positron emission tomography and computed tomography in differential diagnosis between recurrent or residual glioma and treatment-induced brain lesions. Acta Radiol 30:121–128

Biersack HJ, Coenen HH, Stöcklin G, Reichmann K, Bockisch A, Oehr P, Kashab M, Rollmann O (1989) Imaging of brain tumors with 3-[123I]iodo-α-methyl-L-tyrosine and SPECT. J Nucl Med 30:110–112PubMed

Langen KJ, Cohnen HH, Roosen N, Kling P, Muzik O, Herzog H, Kuwert T, Stöcklin G, Feinendegen LE (1990) SPECT studies of brain tumors with L-3-[123]iodo-α-methyltyrosine: comparison with PET, 124IMT and first clinical results. J Nucl Med 31:281–286PubMed

Samnick S, Bader JB, Hellwig D, Moringlane JR, Alexander C, Romeike BF, Feiden W, Kirsch CM (2002) Clinical value of iodine-123-alpha-methyl-L-tyrosine single-photon emission tomography in the differential diagnosis or recurrent brain tumor in patients pretreated for glioma at follow-up. J Clin Oncol 15:396–404CrossRef

Kuwert T, Woesler B, Morgenroth C, Lerch H, Schafers M, Palkovic S, Matheja P, Brandau W, Wassmann H, Schober O (1998) Diagnosis of recurrent glioma with SPECT and iodine-123-alpha-methyl tyrosine. J Nucl Med 39:23–27PubMed

Guth-Tougelidis B, Müller St, Mehdorn MM, Knust EJ, Dutschkla K, Reiners Chr (1995) Uptake of DL-3-123I-iodo-alpha-methyltyrosine in recurrent brain tumors. Nuklearmedizin 34:71–75PubMed

Matheja P, Weckesser M, Rickert Ch, Franzius Ch, Palkovic St, Riemann B, Schober O (2002) I-123-lodo-alpha-methyl tyrosine SPECT in non-parenchymal brain tumours. Nuklearmedizin 41:191–196PubMed

10.

Chang L (1978) A method for attenuation correction in computed tomography. IEEE Trans Nucl Sci 25:638–643

11.

Kuwert T, Morgenroth C, Woesler B, Matheja P, Palkovic S, Vollet B, Schäffers M, Wassmann H, Schober O (1996) Influence of size of regions of interest on the measurement of uptake of iodine-123-α-methyl tyrosine by brain tumors. Nucl Med Commun 17:609–615PubMed

12.

Henze M, Mohammed A, Schlemmer HP, Herfarth KK, Hoffner S, Haufe S, Mier W, Eisenhut M, Debus J, Haberkorn U (2003) PET and SPECT for detection of tumor progression in irradiated low-grade astrocytoma: a receiver-operating-characteristic analysis. J Nucl Med 45:579–586

13.

Byrne TN (1994) Imaging of gliomas. Semin Oncol 21:162–171PubMed

14.

Nelson SJ (1999) Imaging of brain tumors after therapy. Neuroimaging Clin N Am 9:801–819PubMed

15.

Leeds NE, Jackson EF (1994) Current imaging techniques for the evaluation of brain neoplasms. Curr Opin Oncol 6:254–261PubMed

16.

Di Chiro G, Oldfield E, Wright DC, De Michele D, Katz DA, Patronas NJ, Doppman JL, Larson SM, Ito M, Kufta CV (1988) Cerebral necrosis after radiotherapy and/or intraarterial chemotherapy for brain tumors: PET and neuropathologic studies. Am J Roentgenol 150:189–197

17.

Glantz MJ, Hoffman JM, Coleman RE (1991) The role of F18 FDG PET imaging in predicting early recurrence of primary brain tumors. Ann Neurol 29:347–355PubMed

18.

Ishikawa M, Kikuchi H, Miyatake S, Oda Y, Yonekura Y, Nishizawa S (1993) Glucose consumption in recurrent gliomas. Neurosurgery 33:28–33

19.

Ogawa T, Inugami A, Hatazawa J, Kanno I, Murakami M, Yasui N, Mineura K, Uemura K (1996) Clinical positron emission tomography for brain tumors: comparison of fluorodeoxyglucose F 18 and L-methyl-11C-methionine. AJNR Am J Neuroradiol 17:345–353

20.

Bader JB, Samnick S, Moringlane JR, Feiden W, Schaefer A, Kremp S, Kirsch CM (1999) Evaluation of l-3-[123I]iodo-alpha-methyltyrosine SPET and [18F]fluorodeoxyglucose PET in the detection and grading of recurrences in patients pretreated for gliomas at follow-up: a comparative study with stereotactic biopsy. Eur J Nucl Med 26:144–151CrossRefPubMed

21.

Benard F, Romsa J, Hustinx R. (2003) Imaging gliomas with positron emission tomography and single-photon emission computed tomography. Semin Nucl Med 33:148–162CrossRefPubMed

22.

Larcos G, Maisey MN (1996) FDG-PET screening for cerebral metastases in patients with suspected malignancy. Nucl Med Commun 17:197–198PubMed

23.

Griffeth LK, Rich KM, Dehdashti F, Simpson JR, Fusselman MJ, McGuire AH, Siegel BA (1993) Brain metastases from non-central nervous system tumors: evaluation with PET. Radiology 186:13–15PubMed

24.

Rohren EM, Provenzale JM, Barboriak DP, Coleman RE (2003) Screening for cerebral metastases with FDG PET in patients undergoing whole-body staging of non-central nervous system malignancy. Radiology 226:181–187PubMed

25.

Kaschten B, Stevenaert A, Sadzot B, Deprez M, Degueldre C, Del Fiore G, Luxen A, Reznik M (1998) Preoperative evaluation of 54 gliomas by PET with fluorine-18-fluorodeoxyglucose and/or carbon-11-methionine. J Nucl Med 39:778–785PubMed

26.

Tsuyuguchi N, Sunada I, Iwai Y, Yamanaka K, Tanaka K, Takami T, Otsuka Y, Sakamoto S, Ohata K, Goto T, Hara M (2003) Methionine positron emission tomography of recurrent metastatic brain tumor and radiation necrosis after stereotactic radiosurgery: is a differential diagnosis possible? J Neurosurg 98:1056–1064PubMed

27.

Langen KJ, Ziemons K, Kiwit JCW, Herzog H, Kuwert T, Bock WJ, Stöcklin G, Feinendegen LE, Müller-Gärtner HW (1997) 3-[123I]Iodo-alpha-methyltyrosine and [methyl-11C]-L-methionine uptake in cerebral gliomas: a comparative study using SPECT and PET. J Nucl Med 38:517–522PubMed

28.

Pauleit D, Floeth F, Tellmann L, Hamacher H, Hautzel H, Müller HW, Coenen HH, Langen KJ (2004) Comparison of O-(2-18F-fluoroethyl)-L-tyrosine PET and 3-123I-iodo-α-methyl-L-tyrosine SPECT in brain tumors. J Nucl Med 45:374–381PubMed

29.

Plotkin M, Eisenacher J, Bruhn H, Wurm R, Michel R, Stockhammer F, Feussner A, Dudeck O, Wust P, Felix R, Amthauer H (2004) 123I-IMT SPECT and 1H MR-spectroscopy at 3.0 tesla in the differential diagnosis of recurrent or residual gliomas: a comparative study. J Neuro Oncol 70:49–58

30.

Jager PL, Franssen EJ, Kool W, Szabo BG, Hoekstra HJ, Groen HJ, deVires EG, van Imhoff GW, Vaalburg W, Piers DA (1998) Feasibility of tumor imaging using L-3-[iodine-123]-iodo-alpha-methyl-tyrosine in extracranial tumors. J Nucl Med 39:1736–1743PubMed

31.

Flamen P, Bernheim N, Deron P, Caveliers V, Chavatte K, Franken PR, Bossuyt A (1998) Iodine-123 alpha-methyl-l-tyrosine single-photon emission tomography for the visualization of head and neck squamous cell carcinomas. Eur J Nucl Med 25:177–181CrossRefPubMed

32.

Jager PL, Groen HJ, van der Leest A, et al (2001) L-3-[123I]iodo-alpha-methyl- tyrosine SPECT in non-small cell lung cancer: preliminary observations. J Nucl Med 42:579–585PubMed

33.

Willkomm P, Bangard M, Guhlke S, Sartor J, Bender H, Gallkowski U, Reichmann K, Biersack HJ (2002) Comparison of [18F]FDG-PET and L-3[123I]-iodo-alpha-methyl tyrosine (I-123 IMT)-SPECT in primary lung cancer. Ann Nucl Med 16:503–506PubMed

34.

Jager PL, Plaat BE, de Vries EG, Molenaar WM, Vaalburg W, Piers DA, Hoekstra HJ (2000) Imaging of soft-tissue tumors using L-3-[iodine-123]iodo-alpha-methyl-tyrosine single photon emission computed tomography: comparison with proliferative and mitotic activity, cellularity, and vascularity. Clin Cancer Res 6:2252–2259PubMed

35.

Jager PL, Meijer WG, Kema IP, Willemse PH, Piers DA, de Vries EG (2000) L-3-[123I]Iodo-alpha-methyltyrosine scintigraphy in carcinoid tumors: correlation with biochemical activity and comparison with [111In-DTPA-D-Phe1]-octreotide imaging. J Nucl Med 41:1793–1800

36.

Steinert, Boni R, Huch-Boni RA, Capaul R, von Schulthess GK, Westera G (1997) [123I]-alpha-methyltyrosine scintigraphy in malignant melanoma, Nuklearmedizin 36:36–41PubMed

37.

Plotkin M, Amthauer H, Feussner A, Michel R, Ruf J, Wurm R, Felix R (2003) Use of I-123-IMT SPET for planning of radiotherapy in brain metastases and intracranial tumors of non-glial origin J Nucl Med 44 (Suppl):876

38.

Grosu AL, Feldmann H, Dick S, Dzewas B, Nieder C, Gumprecht H, Frank A, Schwaiger M, Molls M, Weber WA (2002) Implications of IMT-SPECT for postoperative radiotherapy planning in patients with gliomas. Int J Radiat Oncol Biol Phys 54:842–854CrossRefPubMed

39.

Nuutinen J, Sonninen P, Lehikoinen P, Sutinen E, Valavaara R, Eronen E, Norrgard S, Kulmala J, Teras M, Minn H (2000) Radiotherapy treatment planning and long-term follow-up with [(11)C] methionine PET in patients with low-grade astrocytoma. Int J Radiat Oncol Biol Phys 48:43–52CrossRefPubMed

40.

Glantz MJ, Hoffman JM, Coleman E, Friedman AH, Hanson MW, Burger PC, Herndon JE II, Meisler WJ, Schold SC Jr (1991) Identification of early recurrence of primary central nervous system tumors by [¹⁸F]fluorodeoxyglucose positron emission tomography. Ann Neurol 29:347–355PubMed

41.

Kahn D, Follett KA, Bushnell DL, Nathan MA, Piper JG, Madsen M, Kirchner PT (1994) Diagnosis of recurrent brain tumor: value of ²⁰¹Tl-SPECT vs. ¹⁸F- fluorodeoxyglucose PET. Am J Roentgenol 163:1459–1465

42.

DiChiro G, Fulham MJ (1993) Virchow’s shackles: can PET-FDG challenge tumor histology? AJNR 14:524–527PubMed

Title: Value of 123I-IMT SPECT for diagnosis of recurrent non-astrocytic intracranial tumours
Authors: Michail Plotkin
Holger Amthauer
Julia Eisenacher
Reinhard Wurm
Roger Michel
Peter Wust
Florian Stockhammer
Rainer Röttgen
Matthias Gutberlet
Juri Ruf
Roland Felix
Publication date: 01-01-2005
Publisher: Springer-Verlag
Published in: Neuroradiology / Issue 1/2005
Print ISSN: 0028-3940
Electronic ISSN: 1432-1920
DOI: https://doi.org/10.1007/s00234-004-1288-x

2024 ASCO Annual Meeting

Springer Medicine

Value of ¹²³I-IMT SPECT for diagnosis of recurrent non-astrocytic intracranial tumours

Abstract

2024 ASCO Annual Meeting

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2005

Co-existence of Chiari malformation type I and Epstein–Barr virus meningoencephalitis in a 3-year-old child: case report and review of the literature

The optic nerve sheath on MRI in acute optic neuritis

Double microcatheter technique for endovascular coiling of wide-neck aneurysms using a new guiding device for the transcarotid approach: technical note

White-matter disease in 18q deletion (18q−) syndrome: magnetic resonance spectroscopy indicates demyelination or increased myelin turnover rather than dysmyelination

Image-guided microneurosurgical management of small cerebral arteriovenous malformations: the value of navigated computed tomographic angiography

Cook detachable coil embolization of a symptomatic, isolated orbital arteriovenous fistula via a superior ophthalmic vein approach